Understand the source comparison
Peptide News January 2026: Research Applications Comparison
Triple GLP-1/GIP/Glucagon Agonists Retatrutide, Mazdutide Multi-receptor activation: GLP-1 (satiety), GIP (insulin secretion), glucagon (lipolysis, thermogenesis) TRIUMPH-1 Phase III: 24.2% weight loss at 48 weeks; FDA Priority Review expected Q2 2026 Metaboli
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Triple GLP-1/GIP/Glucagon Agonists
- Retatrutide, Mazdutide
- Multi-receptor activation: GLP-1 (satiety), GIP (insulin secretion), glucagon (lipolysis, thermogenesis)
- TRIUMPH-1 Phase III: 24.2% weight loss at 48 weeks; FDA Priority Review expected Q2 2026
- Metabolic studies requiring maximal efficacy endpoints; receptor crosstalk investigation; dose-response modeling for multi-agonist systems
- Dual GLP-1/Glucagon Agonists
- Survodutide
- Dual agonism: GLP-1 (incretin effect) + glucagon (hepatic lipid oxidation, energy expenditure)
- SYNCHRONIZE-CVOT: 24% MACE reduction independent of weight loss; cardioprotective mechanism distinct from GLP-1 alone
- Cardiovascular outcome studies; hepatic steatosis models; mechanistic separation of weight-dependent vs. weight-independent metabolic benefits
- Cognitive/Neuroprotective Peptides
- Cerebrolysin, Dihexa, P21, Semax
- Neurotrophic factor upregulation (BDNF, NGF); HGF receptor binding; synaptic plasticity enhancement
- Cell Metabolism Jan 22: Cerebrolysin + Dihexa increased hippocampal BDNF 68% in aged rodents; improved spatial memory
- Aging models; neurodegenerative disease research; cognitive enhancement protocols; synaptic density quantification
- Selective Metabolic Modulators
- SLU PP 332, 5 Amino 1MQ
- ERβ agonism (visceral fat targeting); NNMT inhibition (NAD+ elevation, mitochondrial biogenesis)
- Phase I (SLU PP 332): 12.4% visceral fat reduction without total weight change; Mol Metab Jan 11: 5-Amino-1MQ increased NAD+ and PGC-1α in human adipocytes
- Body composition studies; targeted fat loss research; mitochondrial function assays; non-incretin metabolic pathways
- Immune Modulation Peptides
- Thymosin Alpha 1, Thymalin, KPV
- T cell maturation (thymic peptides); melanocortin receptor anti-inflammatory signaling
- Thymalin Phase II: 18% CD4+ increase in immunocompromised patients; KPV pilot trial: 34% IBD symptom reduction via NF-κB suppression
- Immune reconstitution studies; inflammatory disease models; post-infection recovery protocols; autoimmune research